Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.7629
+0.0088 (1.17%)
At close: Aug 29, 2025, 4:00 PM
0.7693
+0.0064 (0.84%)
After-hours: Aug 29, 2025, 4:51 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,914,533
Market Cap
98.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 3 | 25.00% |
| Dec 31, 2023 | 12 | 1 | 9.09% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | 8 | 2 | 33.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATOS News
- 1 day ago - Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference - PRNewsWire
- 9 days ago - Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer - PRNewsWire
- 17 days ago - Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer - PRNewsWire
- 3 months ago - Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 3 months ago - Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - Accesswire
- 3 months ago - Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - PRNewsWire
- 3 months ago - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire